About Mitochondrial glycine transporter
Mitochondrial glycine transporter (SLC25A38) is a protein
from Homo sapiens identified by UniProt accession
Q96DW6, 304 residues long.
MolForge cross-references it against 0 known binders and
41 disease associations.
Target properties
| Protein name | Mitochondrial glycine transporter |
|---|
| UniProt accession | Q96DW6 |
|---|
| Gene | SLC25A38 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 304 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (41)
Diseases linked to this target (Open Targets).
- Adult-onset autosomal recessive sideroblastic anemia · score 0.79
- autosomal recessive sideroblastic anemia · score 0.70
- genetic disorder · score 0.19
- X-linked sideroblastic anemia 1 · score 0.19
- appendicular lean mass · score 0.15
- schizophrenia · score 0.08
- dentate gyrus volume measurement · score 0.08
- ulnar-mammary syndrome · score 0.08
- acute lymphoblastic leukemia · score 0.07
- platelet crit · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96DW6-F1 | alphafold | PREDICTED | 82.87 | — |
Amino-acid sequence (304 residues)
MIQNSRPSLL QPQDVGDTVE TLMLHPVIKA FLCGSISGTC STLLFQPLDL LKTRLQTLQP SDHGSRRVGM LAVLLKVVRT ESLLGLWKGM SPSIVRCVPG VGIYFGTLYS LKQYFLRGHP PTALESVMLG VGSRSVAGVC MSPITVIKTR YESGKYGYES IYAALRSIYH SEGHRGLFSG LTATLLRDAP FSGIYLMFYN QTKNIVPHDQ VDATLIPITN FSCGIFAGIL ASLVTQPADV IKTHMQLYPL KFQWIGQAVT LIFKDYGLRG FFQGGIPRAL RRTLMAAMAW TVYEEMMAKM GLKS
Explore Mitochondrial glycine transporter with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets